



## Robert Lowsky

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Medicine - Blood & Marrow Transplantation

### CLINICAL OFFICE (PRIMARY)

900 Blake Wilbur Dr

2nd floor Infusion Treatment Area

Stanford, CA 94305

Tel (650) 723-0822      Fax

### Bio

---

#### BIO

Dr. Lowsky has been an academic clinician and medical researcher in hematopoietic cell transplantation for 20 years and has broad experience and expertise in the field. He has designed, written, implemented and participated in single and multi-center federally-funded clinical trials; and has served on the Stanford IRB and SRC for cancer-oriented clinical trials for over 10 years.

#### CLINICAL FOCUS

- Cancer > Blood and Marrow Transplant
- Cancer > Hematology
- Blood and Marrow Transplantation
- Hematology

#### ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Medicine - Blood & Marrow Transplantation
- Member, Stanford Cancer Institute

#### ADMINISTRATIVE APPOINTMENTS

- Director, Apheresis Unit, Blood and Marrow Transplantation, Stanford University, (2005- present)
- Director, BMT Fellowship Program, Blood and Marrow Transplantation, Stanford University, (2002- present)

#### PROFESSIONAL EDUCATION

- Fellowship: Toronto General Hospital Postgraduate Education (1993) Canada
- Residency: Toronto General Hospital Postgraduate Education (1991) Canada
- Internship: Toronto General Hospital Postgraduate Education (1989) Canada
- Medical Education: McGill University Faculty of Medicine (1988) Canada
- Board Certification: Hematology, Royal College of Physicians and Surgeons (1993)
- Board Certification: Internal Medicine, Royal College of Physicians and Surgeons (1992)

- FRCP, Coll of Physicians/Surgs Canada , Hematology (1993)
- FRCP, Coll of Physicians/Surgs Canada , Internal Medicine (1991)
- MD, McGill University , Medicine (1988)

## LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

## Research & Scholarship

---

### CURRENT RESEARCH AND SCHOLARLY INTERESTS

Dr. Lowsky's research is focused on understanding the role of regulatory T cells in the prevention of GVHD and in promoting immune tolerance following organ transplantation.

### CLINICAL TRIALS

- CIBMTR Research Database, Recruiting
- Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs., Recruiting
- 90Y-IBRITUMOMAB Tixetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL, Not Recruiting
- A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease, Not Recruiting
- A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial), Not Recruiting
- A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease, Not Recruiting
- A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1), Not Recruiting
- A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML), Not Recruiting
- Acute Graft-versus-Host Disease Treatment (BMT CTN 0802), Not Recruiting
- Allo BMT in Advanced Leukemia or High Grade Lymphoma, Not Recruiting
- Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102), Not Recruiting
- Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML, Not Recruiting
- Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML), Not Recruiting
- Allogeneic Transplantation From Related Haploidentical Donors, Not Recruiting
- Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies, Not Recruiting
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma, Not Recruiting
- Autologous Stem Cell Rescue for Primary Amyloidosis, Not Recruiting
- Axicabtagene Ciloleucef Expanded Access Study, Not Recruiting
- Bone Marrow Grafting for Leukemia and Lymphoma, Not Recruiting
- CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma, Not Recruiting
- Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801), Not Recruiting
- Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs., Not Recruiting
- Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder, Not Recruiting
- Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study, Not Recruiting
- Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoietic Stem Cell Transplant Patients, Not Recruiting

- Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation, Not Recruiting
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies, Not Recruiting
- Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant, Not Recruiting
- Double Cord Versus Haploidentical (BMT CTN 1101), Not Recruiting
- Evaluation of the Duration of Therapy for Thrombosis in Children, Not Recruiting
- Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies, Not Recruiting
- Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease, Not Recruiting
- Haploid Allogeneic Transplant Using the CliniMACS System, Not Recruiting
- High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma, Not Recruiting
- High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma, Not Recruiting
- Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD), Not Recruiting
- Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant, Not Recruiting
- Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT), Not Recruiting
- Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation, Not Recruiting
- Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AH SCT), Not Recruiting
- MAGE A10<sup>c</sup>###T for Advanced NSCLC, Not Recruiting
- Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma, Not Recruiting
- Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML, Not Recruiting
- Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma, Not Recruiting
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203), Not Recruiting
- Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation, Not Recruiting
- Perinatal Arterial Stroke: A Multi-site RCT of Intensive Infant Rehabilitation (I-ACQUIRE), Not Recruiting
- Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201), Not Recruiting
- Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma, Not Recruiting
- Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD, Not Recruiting
- Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell, Not Recruiting
- Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT, Not Recruiting
- Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG, Not Recruiting
- Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD, Not Recruiting
- Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders, Not Recruiting
- Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies, Not Recruiting
- Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients, Not Recruiting
- Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT, Not Recruiting
- Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT, Not Recruiting
- Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease, Not Recruiting
- Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402), Not Recruiting
- Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors, Not Recruiting

- Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702), Not Recruiting
- Study of Effectiveness of Axicabtagene Ciloleucef Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Not Recruiting
- Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Not Recruiting
- Targeted Therapy of Bronchiolitis Obliterans Syndrome, Not Recruiting
- TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD, Not Recruiting
- Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation, Not Recruiting
- Transplantation for Patients With Chronic Lymphocytic Leukemia, Not Recruiting
- Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation, Not Recruiting
- Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells, Not Recruiting

## Publications

---

### PUBLICATIONS

- **A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.** *Blood*  
Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., Mavroukakis, S., Kuo, A., Cancilla, J., Sahaf, B., Agarwal, N., Kanegai, A. M., Kramer, et al  
2024
- **Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucef in patients with refractory or relapsed large B-cell lymphoma.** *Journal for immunotherapy of cancer*  
Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., Lee, D., Mallampet, J., Elkordy, S., Syal, S., Patil, S., Latchford, T., Sahaf, et al  
2024; 12 (7)
- **CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.** *Blood advances*  
Hamilton, M. P., Craig, E., Gentile Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., Ehlinger, Z., Syal, S., Good, Z., Sworder, B., Schroers-Martin, J., Lu, Y., Muffly, et al  
2024
- **CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.** *Leukemia*  
Schultz, L. M., Jeyakumar, N., Kramer, A. M., Sahaf, B., Srinagesh, H., Shiraz, P., Agarwal, N., Hamilton, M., Erickson, C., Jacobs, A., Moon, J., Baggott, C., Arai, et al  
2024
- **Development of immunosuppressive myeloid cells to induce tolerance in solid organ and hematopoietic cell transplant recipients.** *Blood advances*  
Jensen, K. P., Hongo, D., Ji, X., Zheng, P., Pawar, R. D., Wu, H., Busque, S., Scandling, J. D., Shizuru, J. A., Lowsky, R., Shori, A., Dutt, S., Waters, et al  
2021
- **Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.** *Blood advances*  
Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., Spiegel, J. Y., Arai, S., Frank, M. J., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, et al  
2021; 5 (16): 3147-3151
- **CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.** *Nature medicine*  
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., Iglesias, M., Younes, S., Natkunam, et al  
2021
- **Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.** *Bone marrow transplantation*

- Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., Shiraz, P., Rezvani, A. R., Frank, M. J., Weng, W., Meyer, E., Shizuru, J. A., Arai, et al  
2021
- **Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report**  
Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M., Lowsky, R., Brown, J., Johnston, L., Rezvani, A., Frank, M., Muffly, et al  
SPRINGER NATURE.2021: 181
  - **Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.** *Transplantation and cellular therapy*  
Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., Shizuru, J. A., Johnston, L., Arai, S., Weng, W., Lowsky, R., Rezvani, A. R., Meyer, et al  
2021
  - **Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.** *Transplantation and cellular therapy*  
Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., Frank, M. J., Weng, W., Lowsky, R., Rezvani, A., Meyer, E. H., Negrin, R., Miklos, et al  
2021
  - **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.** *Blood advances*  
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al  
2021; 5 (1): 143-155
  - **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma** *BLOOD ADVANCES*  
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al  
2021; 5 (1): 143–55
  - **Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.** *Leukemia*  
Merryman, R. W., Castagna, L. n., Giordano, L. n., Ho, V. T., Corradini, P. n., Guidetti, A. n., Casadei, B. n., Bond, D. A., Jaglowski, S. n., Spinner, M. A., Arai, S. n., Lowsky, R. n., Shah, et al  
2021
  - **Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.** *Blood advances*  
Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., Tamaresis, J. S., Negrin, R. S., Johnston, L., Arai, S., Shizuru, J. A., Lowsky, R., Meyer, et al  
2021
  - **Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*  
Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., Rezvani, A., Frank, M. J., Weng, W., Meyer, E., Shizuru, J., Arai, S., Negrin, et al  
2020
  - **Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.**  
Lemieux, C., Muffly, L. S., Iberri, D., Rezvani, A., Lowsky, R., Frank, M., Craig, J. K., Liedtke, M., Negrin, R., Weng, W., Meyer, E., Johnston, L. J., Shizuru, et al  
LIPPINCOTT WILLIAMS & WILKINS.2020
  - **Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).**  
Tam, E., Iberri, D., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M., Lowsky, R., Rezvani, A., Negrin, R., Meyer, E., Arai, S., Johnston, L. J., Shizuru, et al  
LIPPINCOTT WILLIAMS & WILKINS.2020
  - **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era**

Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R. S., Rezvani, A., Shiraz, P., Shizuru, J. A., Sidana, S., Weng, W., Cunanan, et al  
ELSEVIER SCIENCE INC.2020: S106

- **Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal.** *Science translational medicine*  
Busque, S. n., Scandling, J. D., Lowsky, R. n., Shizuru, J. n., Jensen, K. n., Waters, J. n., Wu, H. H., Sheehan, K. n., Shori, A. n., Choi, O. n., Pham, T. n., Fernandez Vina, M. A., Hoppe, et al  
2020; 12 (528)
- **CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.** *Blood*  
Baird, J. H., Frank, M. J., Craig, J. n., Patel, S. n., Spiegel, J. Y., Sahaf, B. n., Oak, J. S., Younes, S. n., Ozawa, M. n., Yang, E. n., Natkunam, Y. n., Tamaresis, J. S., Ehlinger, et al  
2020
- **Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.** *Blood advances*  
Weng, W. K., Arai, S. n., Rezvani, A. n., Johnston, L. n., Lowsky, R. n., Miklos, D. n., Shizuru, J. n., Muffly, L. n., Meyer, E. n., Negrin, R. S., Wang, E. n., Almazan, T. n., Million, et al  
2020; 4 (18): 4474–82
- **Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.** *Bone marrow transplantation*  
Lemieux, C. n., Muffly, L. S., Rezvani, A. n., Lowsky, R. n., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L. J., Liedtke, M. n., Negrin, R. n., Weng, W. K., Meyer, E. n., Shizuru, et al  
2020
- **Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*  
Giralt, S., Costa, L. J., Maloney, D., Krishnan, A., Fei, M., Antin, J. H., Brunstein, C., Geller, N., Goodman, S., Hari, P., Logan, B., Lowsky, R., Qazilbash, et al  
2019
- **Combined kidney and hematopoietic cell transplantation to induce mixed chimerism and tolerance.** *Bone marrow transplantation*  
Lowsky, R., Strober, S.  
2019; 54 (Suppl 2): 793–97
- **Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Narayan, R., Benjamin, J. E., Shah, O., Tian, L., Tate, K., Armstrong, R., Xie, B. J., Lowsky, R., Laport, G., Negrin, R. S., Meyer, E. H.  
2019; 25 (7): 1293–1303
- **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients** *JCI INSIGHT*  
Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., Tang, S., Baker, J., Armstrong, R., Tate, K., Tadisco, C., Arai, S., Johnston, et al  
2019; 4 (10)
- **Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Cohen, J. A., Baldassari, L. E., Atkins, H. L., Bowen, J. D., Bredeson, C., Carpenter, P. A., Corboy, J. R., Freedman, M. S., Griffith, L. M., Lowsky, R., Majhail, N. S., Muraro, P. A., Nash, et al  
2019; 25 (5): 845–54
- **AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR TREATMENT-REFRACTORY RELAPSING MULTIPLE SCLEROSIS: POSITION STATEMENT FROM THE AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*  
Cohen, J. A., Baldassari, L. E., Atkins, H. L., Bowen, J. D., Bredeson, C., Carpenter, P. A., Corboy, J. R., Freedman, M. S., Griffith, L. M., Lowsky, R., Majhail, N. S., Muraro, P. A., Nash, et al  
2019
- **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.** *JCI insight*  
Meyer, E. H., Laport, G. n., Xie, B. J., MacDonald, K. n., Heydari, K. n., Sahaf, B. n., Tang, S. W., Baker, J. n., Armstrong, R. n., Tate, K. n., Tadisco, C. n., Arai, S. n., Johnston, et al

2019; 4 (10)

- **Assessment by Extended-Coverage Next-Generation Sequencing Typing of DPA1 and DPB1 Mismatches in Siblings Matching at HLA-A, -B, -C, -DRB1, and -DQ Loci.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*  
Mariano, L. n., Zhang, B. M., Osoegawa, K. n., Lowsky, R. n., Fernandez-Vina, M. n.  
2019
- **Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.** *Blood advances*  
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, J. A., Weng, et al  
2019; 3 (16): 2454–64
- **Donor-derived CIK Cell Infusion as Consolidation after Non-myeloablative Allogeneic Transplant for Myeloid Neoplasms.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*  
Narayan, R. n., Benjamin, J. E., Shah, O. n., Tian, L. n., Tate, K. n., Armstrong, R. n., Xie, B. n., Lowsky, R. n., Laport, G. n., Negrin, R. S., Meyer, E. H.  
2019
- **Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort**  
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, et al  
AMER SOC HEMATOLOGY.2018
- **Elevated Axicabtagene Ciloleucef (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma**  
Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., Latchford, T., Villa, B., Cancilla, J., Oak, J., Natkunam, Y., Long, S. R., Arai, et al  
AMER SOC HEMATOLOGY.2018
- **Relationship Between Mixed Chimerism and Acceptance of HLA-matched and -Mismatched Kidney Transplants after Withdrawal of Immunosuppressive Drugs**  
Busque, S., Scandling, J., Lowsky, R., Shizuru, J., Jensen, K., Shori, A., Hoppe, R., Engleman, E., Meyer, E., Strober, S.  
LIPPINCOTT WILLIAMS & WILKINS.2018: S393
- **Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation** *BLOOD ADVANCES*  
Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al  
2018; 2 (6): 681–90
- **Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells**  
Meyer, E., Laport, G. G., Tantsura, I., Tang, S., Sahaf, B., Rangarajan, K., Armstrong, R., Tate, K., Tudisco, C., Sheehan, K., Arai, S., Johnston, L., Muffly, et al  
ELSEVIER SCIENCE INC.2018: S145
- **Macrochimerism and clinical transplant tolerance.** *Human immunology*  
Scandling, J. D., Busque, S., Lowsky, R., Shizuru, J., Shori, A., Engleman, E., Jensen, K., Strober, S.  
2018
- **Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.** *Blood advances*  
Spinner, M. A., Advani, R. H., Hoppe, R. T., Lowsky, R. n., Muffly, L. S.  
2018; 2 (13): 1547–50
- **Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., Meyer, E., Muffly, L., Negrin, R., Rezvani, A., Shizuru, J., Weng, W., Johnston, et al  
2017; 23 (10): 1744–48
- **PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.** *Blood*

Haverkos, B. M., Abbott, D., Hamadani, M., Armand, P., Flowers, M. E., Merryman, R., Kamdar, M., Kanate, A. S., Saad, A., Mehta, A., Ganguly, S., Fenske, T. S., Hari, et al  
2017

- **HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.** *Blood advances*  
Spinner, M. A., Fernández-Viña, M. n., Creary, L. E., Quinn, O. n., Elder, L. n., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Shizuru, J. A., Weng, et al  
2017; 1 (17): 1347–57
- **Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors**  
Spinner, M. A., Vina, M., Elder, L., Arai, S., Johnston, L., Meyer, E., Miklos, D., Muffly, L., Negrin, R. S., Shizuru, J., Weng, W., Laport, G. G., Strober, et al  
AMER SOC HEMATOLOGY.2016
- **Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation**  
Muffly, L. S., Sheehan, K., Armstrong, R., Tate, K., Tudisco, C., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al  
AMER SOC HEMATOLOGY.2016
- **The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Alousi, A. M., Anasetti, C., Antin, J. H., Appelbaum, F. R., Bashey, A., Confer, D. L., Devine, S. M., DiFronzo, N., Giralto, S. A., Grupp, S. N., Hari, P. N., Heslop, H. E., Horowitz, et al  
2016; 22 (10): 1747-1757
- **Pregnancy Complicated by Gorham-Stout Disease and Refractory Chylothorax.** *AJP reports*  
Hellyer, J., Oliver-Allen, H., Shafiq, M., Tolani, A., Druzin, M., Jeng, M., Rockson, S., Lowsky, R.  
2016; 6 (4): e355-e358
- **Immunosuppressive myeloid cells in patients given combined kidney and hematopoietic cell transplants in a tolerance protocol with TLI and ATG conditioning**  
Jensen, K., Scandling, J., Busque, S., Shizuru, J., Lowsky, R., Saraswathula, A., Sheehan, K., Shori, A., Engleman, E., Strober, S.  
LIPPINCOTT WILLIAMS & WILKINS.2016: S5
- **Relationship between mixed chimerism and clinical tolerance after combined kidney and hematopoietic cell transplantation using total lymphoid irradiation and antithymocyte globulin conditioning**  
Busque, S., Scandling, J. D., Shizuru, J., Lowsky, R., Shori, A., Jensen, K., Engleman, E., Strober, S.  
LIPPINCOTT WILLIAMS & WILKINS.2016: S245
- **Immune Characterization of Ibrutinib Therapy Following AlloHct That Provides GVL Benefit without Gvhd**  
Sahaf, B., Ryan, C. E., Rezvani, A., Nakasone, H., Otani, J., Coutre, S., Lowsky, R., Negrin, R., Miklos, D. B.  
ELSEVIER SCIENCE INC.2016: S412
- **Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin**  
Nakasone, H., Miklos, D. B., Meyer, E., Rezvani, A., Muffly, L., Weng, W., Arai, S., Johnston, L., Laport, G. G., Shizuru, J. A., Negrin, R., Strober, S., Lowsky, et al  
ELSEVIER SCIENCE INC.2016: S204–S205
- **Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms**  
Narayan, R., Benjamin, J., Laport, G., Tian, L., Tate, K., Elder, L., Galvez, L., Armstrong, R., Sheehan, K., Lowsky, R., Arai, S., Johnston, L., Miklos, et al  
AMER SOC HEMATOLOGY.2015
- **Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.** *Haematologica*  
Nakasone, H., Remberger, M., Tian, L., Brodin, P., Sahaf, B., Wu, F., Mattsson, J., Lowsky, R., Negrin, R., Miklos, D. B., Meyer, E.  
2015; 100 (11): 1477-1485



- **Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning** *BONE MARROW TRANSPLANTATION*  
Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., Laport, G. G., Miklos, D. B., Benjamin, J. E., JOHNSTON, L. J., Arai, S., Weng, W., Negrin, et al  
2015; 50 (10): 1286-1292
- **Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipilimumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas.**  
Khodadoust, M., Chu, M., Czerwinski, D., McDonald, K., Long, S., Kohrt, H., Hoppe, R. T., Advani, R. H., Lowsky, R., Levy, R.  
AMER SOC CLINICAL ONCOLOGY.2015
- **Chimerism, Graft Survival, and Withdrawal of Immunosuppressive Drugs in HLA Matched and Mismatched Patients After Living Donor Kidney and Hematopoietic Cell Transplantation.** *American journal of transplantation*  
Scandling, J. D., Busque, S., Shizuru, J. A., Lowsky, R., Hoppe, R., Dejbakhsh-Jones, S., Jensen, K., Shori, A., Strober, J. A., Lavori, P., Turnbull, B. B., Engleman, E. G., Strober, et al  
2015; 15 (3): 695-704
- **Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Strategy**  
Nakasone, H., Remberger, M., Tian, L., Brodin, P., Sahaf, B., Wu, F., Mattsson, J., Lowsky, R., Negrin, R., Miklos, D. B., Meyer, E.  
ELSEVIER SCIENCE INC.2015: S340–S341
- **Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.** *Bone marrow transplantation*  
Percival, M. M., Medeiros, B. C., Tian, L. n., Robeson, S. n., Laport, G. G., Johnston, L. J., Shizuru, J. A., Miklos, D. B., Arai, S. n., Weng, W. K., Negrin, R. S., Lowsky, R. n.  
2015
- **Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Intensity**  
Nakasone, H., Remberger, M., Tian, L., Brodin, P., Sahaf, B., Wu, F., Lowsky, R., Mattsson, J., Negrin, R. S., Miklos, D. B., Meyer, E.  
AMER SOC HEMATOLOGY.2014
- **Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sezary Syndrome (SS)**  
Weng, W., Armstrong, R., Arai, S., Johnston, L., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Benjamin, J. E., Negrin, R. S., Reddy, S., Million, L., Hoppe, et al  
AMER SOC HEMATOLOGY.2014
- **Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.** *Biology of blood and marrow transplantation*  
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., Johnston, L., Miklos, D. B., Shizuru, J. A., Weng, W., Negrin, R. S., Lowsky, R.  
2014; 20 (6): 837-843
- **Outcome of Tandem Autologous/Allogeneic Hematopoietic Cell Transplantation in High-Risk Non Hodgkin's Lymphoma Patients: Stanford University Experience**  
Wudhikarn, K., Lavori, P., Arai, S., Johnston, L., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Hoppe, R. T., Benjamin, J., Meyer, E., Negrin, R., Weng, et al  
ELSEVIER SCIENCE INC.2014: S164
- **Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation.** *Clinical immunology*  
Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., Tibshirani, R. J., Strober, S., Sarwal, M., Lowsky, R.  
2013; 148 (1): 124-135
- **Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation** *BMT Tandem Meetings*  
Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H., Shizuru, J. A., Laport, G. G., Miklos, D. B., Benjamin, J., Johnston, L., Arai, S., Weng, W., Negrin, R., Strober, et al  
ELSEVIER SCIENCE INC.2013: S154–S155
- **TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN** *BMT Tandem Meetings*  
Benjamin, J., Chhabra, S., Kohrt, H., Laport, G. G., Arai, S., Johnston, L., Miklos, D. B., Shizuru, J. A., Weng, W., Negrin, R., Lowsky, R.

ELSEVIER SCIENCE INC.2013: S113–S114

- **Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation**  
Kohrt, H. E., Tian, L., Li, L., Alizadeh, A. A., Hsieh, S., Strober, S., Sarwal, M., Lowsky, R.  
AMER SOC HEMATOLOGY.2012
- **Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence** *BLOOD*  
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., Shizuru, J. A., Johnston, L. J., Laport, G. G., Weng, W., Benjamin, J. E., Schaenman, J., Brown, et al  
2012; 119 (25): 6145-6154
- **Rare cells predict GVHD.** *Blood*  
Strober, S., Lowsky, R.  
2012; 119 (21): 4820-4821
- **Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants** *AMERICAN JOURNAL OF TRANSPLANTATION*  
Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Sarwal, M., Millan, M. T., Shizuru, J. A., Lowsky, R., Engleman, E. G., Strober, S.  
2012; 12 (5): 1133-1145
- **Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation** *BONE MARROW TRANSPLANTATION*  
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., Brown, J., Laport, G., Lowsky, R., Miklos, D., Shizuru, J., Sheehan, K., Lavori, P., Negrin, et al  
2012; 47 (4): 581-588
- **Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma** *BONE MARROW TRANSPLANTATION*  
Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., Lowsky, R., Miklos, D. B., Arai, S., Weng, W., Laport, G. G., Stockerl-Goldstein, K.  
2012; 47 (4): 516-521
- **Donor Immunization with WT1 Peptide Augments Anti-Leukemic Activity After MHC-Matched Bone Marrow Transplantation** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*  
Kohrt, H. E., Mueller, A. M., Baker, J. B., Goldstein, M. J., Newell, E., Dutt, S., Czerwinski, D. K., Lowsky, R., Strober, S.  
AMER SOC HEMATOLOGY.2011: 827–28
- **Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation.** *Blood*  
Kohrt, H. E., Müller, A., Baker, J., Goldstein, M. J., Newell, E., Dutt, S., Czerwinski, D., Lowsky, R., Strober, S.  
2011; 118 (19): 5319-5329
- **Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation** *BLOOD*  
Kohrt, H. E., Mueller, A., Baker, J., Goldstein, M. J., Newell, E., Dutt, S., Czerwinski, D., Lowsky, R., Strober, S.  
2011; 118 (19): 5319-5329
- **Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., Johnston, L. J., Shizuru, J. A., Miklos, D., Arai, S., Benjamin, J. E., Weng, W., Negrin, et al  
2011; 17 (11): 1679-1687
- **Translational studies in hematopoietic cell transplantation: Treatment of hematologic malignancies as a stepping stone to tolerance induction** *SEMINARS IN IMMUNOLOGY*  
Strober, S., Spitzer, T. R., Lowsky, R., Sykes, M.  
2011; 23 (4): 273-281
- **Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY** *BONE MARROW TRANSPLANTATION*  
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., Lowsky, R., Miklos, D., Shizuru, J., Blume, K., Negrin, R., Johnston, L.  
2011; 46 (2): 192-199

- **Noninvasive Prediction of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation by Gene Expression Profiling** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*  
Kohrt, H. E., Li, L., Alizadeh, A. A., Goldstein, M. J., Strober, S., Sarwal, M., Lowsky, R.  
AMER SOC HEMATOLOGY.2010: 393-94
- **Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia** *BRITISH JOURNAL OF HAEMATOLOGY*  
Jones, C. D., Arai, S., Lowsky, R., Tyan, D. B., Zehnder, J. L., Miklos, D. B.  
2010; 150 (5): 637-639
- **Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Weng, W., Lavori, P. W., Blume, K. G., Negrin, R. S., Horning, et al  
2010; 16 (8): 1145-1154
- **NKT cells, Treg, and their interactions in bone marrow transplantation** *EUROPEAN JOURNAL OF IMMUNOLOGY*  
Kohrt, H. E., Pillai, A. B., Lowsky, R., Strober, S.  
2010; 40 (7): 1862-1869
- **Noninvasive Prediction of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation by Gene Expression Profiling.** *10th American Transplant Congress*  
Li, L., Kohrt, H., Heish, S., Alizadeh, A., Laport, G., Shizuru, J., Negrin, R., Strober, S., Lowsky, R., Sarwal, M.  
WILEY-BLACKWELL.2010: 483-483
- **Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure** *BONE MARROW TRANSPLANTATION*  
Benjamin, J. E., Chen, G. L., Cao, T. M., Cao, P. D., Wong, R. M., Sheehan, K., Shizuru, J. A., JOHNSTON, L. J., Negrin, R. S., Lowsky, R., Laport, G. G.  
2010; 45 (2): 303-309
- **Gene Arrays May Predict Stable Clinical Kidney Tolerance and Support Safe Immunosuppression Withdrawal** *American-Society-of-Transplantation Annual Scientific Exchange*  
Sarwal, M. M., Li, L., Hsieh, S., Lowsky, R., Busque, S., Scandling, J., Jones, S., Strober, S.  
WILEY-BLACKWELL PUBLISHING, INC.2010: 1-1
- **Nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin: an update** *CURRENT OPINION IN HEMATOLOGY*  
Kohrt, H., Lowsky, R.  
2009; 16 (6): 460-465
- **TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors** *BLOOD*  
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., Johnston, L. J., Arai, S., Weng, W., Hoppe, R. T., Lavori, P. W., Blume, K. G., Negrin, et al  
2009; 114 (5): 1099-1109
- **Total lymphoid irradiation for graft-versus-host disease protection.** *Current opinion in oncology*  
Kohrt, H., Lowsky, R.  
2009; 21: S23-6
- **Gene Arrays May Predict Stable Clinical Tolerance and Support Safe Immunosuppression Withdrawal.** *9th Joint Meeting of the American-Society-of-Transplant-Surgeon/American-Society-of-Transplantation*  
Sarwal, M. M., Li, L., Hsieh, S., Lowsky, R., Busque, S., Scandling, J., Jones, S., Strober, S.  
WILEY-BLACKWELL.2009: 280-280
- **Chimerism and Tolerance after Combined Human Kidney and Hematopoietic Cell Transplantation Using Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*  
Lowsky, R., Shizuru, J., Busque, S., Scandling, J., Sarwal, M., Jones, S., Benike, C., Hoppe, R., Engleman, E., Strober, S.  
AMER SOC HEMATOLOGY.2008: 758-58

- **Tolerance and chimerism after renal and hematopoietic-cell transplantation.** *New England journal of medicine*  
Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Millan, M. T., Shizuru, J. A., Hoppe, R. T., Lowsky, R., Engleman, E. G., Strober, S.  
2008; 358 (4): 362-368
- **Brief report: Tolerance and chimerism after renal and hematopoietic-cell transplantation** *NEW ENGLAND JOURNAL OF MEDICINE*  
Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Millan, M. T., Shizuru, J. A., Hoppe, R. T., Lowsky, R., Engleman, E. G., Strober, S.  
2008; 358 (4): 362-368
- **Thymoglobulin and regulatory T cells in organ and hematopoietic cell transplantation** *TRANSPLANTATION*  
Lowsky, R.  
2007; 84 (11): S20-S26
- **RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines** *ONCOGENE*  
Pastural, E., Takahashi, N., Dong, W., Bainbridge, M., Hull, A., Pearson, D., Huang, S., Lowsky, R., DeCoteau, J. F., Geyer, C. R.  
2007; 26 (11): 1586-1594
- **High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., Shizuru, J. A., Blume, K. G., Negrin, R. S., Stockerl-Goldstein, K. E.  
2006; 12 (7): 703-711
- **Total lymphoid irradiation and transplantation tolerance** *CURRENT OPINION IN ORGAN TRANSPLANTATION*  
Lowsky, R., Negrin, R. S.  
2006; 11 (1): 54-61
- **Protective conditioning for acute graft-versus-host disease** *NEW ENGLAND JOURNAL OF MEDICINE*  
Lowsky, R., Takahashi, T., Liu, Y. P., Dejbakhsh-Jones, S., GRUMET, F. C., Shizuru, J. A., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Hoppe, R. T., Bloch, D. A., Blume, K. G., Negrin, et al  
2005; 353 (13): 1321-1331
- **A technique of bone marrow collection from vertebral bodies of cynomolgus macaques for transplant studies** *JOURNAL OF SURGICAL RESEARCH*  
Flores, M. G., Holm, B., Larson, M. J., Lau, M. K., Si, M. S., Lowsky, R., Rousvoal, G., GRUMET, F. C., Strober, S., Hoppe, R., Reitz, B. A., Borie, D. C.  
2005; 124 (2): 280-288
- **Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose** *BLOOD*  
Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Stuart, M. J., GRUMET, F. C., Negrin, R. S., Lowsky, R.  
2005; 105 (6): 2300-2306
- **CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies** *EXPERIMENTAL HEMATOLOGY*  
Cao, T. M., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., Negrin, R. S., Lowsky, R.  
2005; 33 (3): 279-285
- **Short tandem repeat analysis to monitor chimerism in *Macaca fascicularis*** *AMERICAN JOURNAL OF TRANSPLANTATION*  
Lau, M., Vayntrub, T., GRUMET, F. C., Lowsky, R., Strober, S., Hoppe, R., Larson, M., Holm, B., Reitz, B., Borie, D.  
2004; 4 (9): 1543-1548
- **Approaches to transplantation tolerance in humans** *TRANSPLANTATION*  
Strober, S., Lowsky, R. J., Shizuru, J. A., Scandling, J. D., Millan, M. T.  
2004; 77 (6): 932-936
- **Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside** *EUROPEAN JOURNAL OF HAEMATOLOGY*  
Patel, M., Ezzat, W., Pauw, K. L., Lowsky, R.  
2001; 67 (5-6): 318-321